← Eichor
Condition: Anca Associated Vasculitis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Anca Associated Vasculitis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Phase 1 · 2 location(s) · Beijing GoBroad Hospital · NCT06980597Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel
EARLY_Phase 1 · 1 location(s) · Changhai Hospital · NCT07246096Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Phase N/A · 1 location(s) · National Institute of Arthritis and Musculoskeletal and Skin · NCT02257866Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Peking University Third Hospital · NCT06828042Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07010250CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07315087BDB-001 Phase III Trial in ANCA-Associated Vasculitis
Phase 3 · 65 location(s) · Staidson (Beijing) Biopharmaceuticals Co., Ltd · NCT07168161A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07104721Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Charact
Phase N/A · 1 location(s) · Medical University Innsbruck · NCT04538937A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
EARLY_Phase 1 · 1 location(s) · Nanjing Bioheng Biotech Co., Ltd. · NCT07203404Vasculitis Pregnancy Registry
Phase N/A · 1 location(s) · University of Pennsylvania · NCT02593565Rescue of Nephrons With ALE.F02 (RENAL-F02)
Phase 2 · 51 location(s) · Alentis Therapeutics AG · NCT06047171A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06978647CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07305116CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06941129Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
Phase 3 · 2 location(s) · Ottawa Hospital Research Institute · NCT06983821An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
NA · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06379646Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06614270Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
Phase 2 · 35 location(s) · Novartis Pharmaceuticals · NCT06868290Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
Phase 4 · 22 location(s) · Chiba University · NCT06611696Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06056921MTS109 in Patients With Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Shanghai Changzheng Hospital · NCT07526350Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
Phase 1 · 2 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07236801Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)
Phase 4 · 1 location(s) · Chinese SLE Treatment And Research Group · NCT05962840A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
Phase 3 · 15 location(s) · AstraZeneca · NCT06512883Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Va
Phase 2 · 78 location(s) · Alexion Pharmaceuticals, Inc. · NCT07160608Early-access Avacopan in Real-world ANCA-associated Vasculitis
Phase N/A · 1 location(s) · Leiden University Medical Center · NCT06794827Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
EARLY_Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07507201Biocollection of Patients With ANCA Associated Vasculitis
NA · 1 location(s) · University Hospital, Brest · NCT05364892VCRC Tissue Repository
Phase N/A · 8 location(s) · University of Pennsylvania · NCT02967068
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.